Oncogenetic testing is a diagnostic method that makes it possible to identify a genetic predisposition to the development of oncological diseases. The analysis helps assess the risk of hereditary cancer, detect mutations that influence tumor growth, and select personalized treatment strategies.
When is oncogenetic testing required?
In the presence of cancer cases among close relatives. In situations involving the diagnosis of hereditary mutations predisposing to breast, ovarian, colorectal, prostate, and lung cancers. For the identification of oncogenic mutations prior to pregnancy planning, as well as for individualized therapy selection in patients with already diagnosed tumors. For follow-up after oncological treatment and for predicting the risk of recurrence.
Types of oncogenetic testing
- Analysis of mutations in the BRCA1 and BRCA2 genes – assessment of the risk of breast and ovarian cancer.
- Testing of APC, MLH1, MSH2, MSH6 genes – diagnosis of hereditary colorectal cancer (Lynch syndrome, polyposis).
- Detection of TP53, PTEN, ATM mutations – analysis of predisposition to soft tissue and brain tumors.
- Pharmacogenetics in oncology – selection of personalized chemotherapy and targeted therapy.
- Analysis of circulating tumor DNA – a non-invasive method for early cancer detection and recurrence monitoring.
How is the test performed?
Venous blood, buccal epithelium, or a tumor tissue sample is used for analysis. Depending on the diagnostic method, results may be available within several days or weeks. Following analysis, the data are interpreted by medical geneticists and oncologists.
Key advantages of oncogenetic testing in Belarus
Early identification of cancer predisposition, enabling prevention and regular monitoring. Selection of personalized treatment based on tumor-specific mutations. High diagnostic accuracy, minimal invasiveness, and the possibility of family screening.
Belarusian laboratories employ modern DNA sequencing technologies that ensure accuracy and reliability of diagnostics. Experienced geneticists and oncologists interpret the data and assist in developing effective prevention and treatment strategies.
